FY2025 Earnings Estimate for LXEO Issued By Leerink Partnrs

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Lexeo Therapeutics in a report issued on Monday, March 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($3.18) per share for the year, down from their prior estimate of ($3.00). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2026 earnings at ($2.67) EPS and FY2027 earnings at ($2.63) EPS.

LXEO has been the topic of a number of other reports. Leerink Partners dropped their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday, March 24th. Royal Bank of Canada dropped their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday. Finally, Chardan Capital reiterated a “buy” rating and set a $25.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $22.80.

Lexeo Therapeutics Stock Down 0.2 %

LXEO opened at $4.10 on Thursday. The company has a fifty day moving average of $4.05 and a two-hundred day moving average of $6.58. The stock has a market capitalization of $135.57 million, a price-to-earnings ratio of -1.30 and a beta of 3.85. Lexeo Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.09.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of hedge funds have recently made changes to their positions in LXEO. Geode Capital Management LLC increased its position in shares of Lexeo Therapeutics by 86.5% during the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock worth $5,003,000 after purchasing an additional 256,635 shares in the last quarter. State Street Corp boosted its stake in Lexeo Therapeutics by 29.4% during the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock worth $2,296,000 after purchasing an additional 57,674 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Lexeo Therapeutics during the third quarter worth $11,307,000. Barclays PLC raised its position in shares of Lexeo Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after buying an additional 31,057 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Lexeo Therapeutics by 18.9% in the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after buying an additional 599,203 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.